Cancer-derived extracellular succinate: a driver of cancer metastasis
Comparative study of magnesium, sodium valproate, and concurrent magnesium-sodium valproate therapy in the prevention of migraine headaches: a randomized controlled double-blind trial
Reduces dark spots and evens out skin tone
Frequently Asked Questions Can natural supplements replace prescribed GLP-1 medications for diabetes
Matveyenko AV, Dry S, Cox HI, Moshtaghian A, Gurlo T, Galasso R, Butler AE, and Butler PC
The master complaint filed in MDL 3094 asserts multiple causes of action against the defendants: Failure to warn of gastroparesis and persistent gastrointestinal injuries despite clinical trial data and post-market surveillance revealing these risks Negligent design and testing of GLP-1 receptor agonists without adequate safety protocols Breach of express and implied warranties regarding drug safety and efficacy Fraudulent concealment of known risks from regulatory agencies, physicians, and patients Violations of state consumer protection and unfair trade practices laws The lawsuit claims include negligent misrepresentation in marketing materials that emphasized benefits while minimizing serious adverse events The failure to warn allegations form the strongest foundation of these claims, as internal documents and regulatory timelines reveal a pattern of delayed safety communications to the medical community
